Compare ProShares UltraPro QQQ ETF (TQQQ) vs GeneDx Holdings Corp (WGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ProShares UltraPro QQQ ETF vs GeneDx Holdings Corp — how do they compare? ProShares UltraPro QQQ ETF trades at $81.4 (market cap $38.74B), while GeneDx Holdings Corp trades at $67.29 (market cap $2.02B). The key difference: ProShares UltraPro QQQ ETF is far larger — about 19.2× GeneDx Holdings Corp's market cap, and ProShares UltraPro QQQ ETF is trading nearer its 52-week high, GeneDx Holdings Corp nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold ProShares UltraPro QQQ ETF for 24 Days and GeneDx Holdings Corp for 19 Days on average.
| TQQQ | WGS | |
|---|---|---|
Market Cap | $38.74B | $2.02B |
Volume | 65,384,797 | 734,640 |
Sector | Leveraged / Inverse | Health |
52-Week High | $87.22 | $167.51 |
52-Week Low | $37.89 | $34.51 |
Typical Hold Time | 24 Days | 19 Days |
Enterprise Value | — | $2.05B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TQQQ trades at $81.16, down 2.92% on the day, with technical indicators showing a bullish overall signal despite recent selling pressure. The leveraged ETF structure amplifies both gains and losses, with recent news highlighting hidden costs beyond the stated 0.82% expense ratio. Support levels are established at $78 and $76, while resistance sits at $83 and $85.
The outlook for TQQQ remains tied to Nasdaq-100 performance and tech sector momentum, though volatility decay and financing costs present significant long-term risks. Current technical positioning suggests potential for near-term upside if support holds, but investors should be cautious of amplified losses during market downturns.
GeneDx (WGS) trades at $68.09, down 0.64% today, with a bearish technical signal despite bullish oscillators showing oversold conditions. The company reported mixed Q2 2026 results with revenue beating expectations but negative profitability metrics, including a -23.4% net income margin. Recent news highlights product launches and industry recognition, while analyst consensus remains strongly bullish with a $81 price target.
The stock presents a growth opportunity in genomic testing with strong analyst support, but faces significant execution risks from persistent losses and high valuation multiples. Key catalysts include continued revenue growth and path to profitability, while risks include competitive pressures and cash flow challenges from negative operating cash flow in 2026.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About ProShares UltraPro QQQ ETF
TQQQ is a leveraged ETF that seeks daily investment results, before fees and expenses, that correspond to three times (3x) the daily performance of the Nasdaq-100 Index. It is one of the most liquid and actively traded instruments in the market, designed for sophisticated traders to amplify short-term bullish exposure to large-cap non-financial growth stocks, predominantly in the technology and communication sectors.
Read more on TQQQ →About GeneDx Holdings Corp
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →
